Is Eli Lilly (NYSE:LLY) Seeing Institutional Interest Shift?
Highlights,SkyOak Wealth LLC adjusted its stake in Eli Lilly (NYSE:LLY) in the fourth quarter, reducing its position by a small margin.,Several other institutional firms also modified their holdings in the company during recent quarters.,Institutional own...
Eli Lilly And Co (LLY) Stock Sees Market Value Hit $769.35 billion: What Are the Implications?
Eli Lilly And Co (LLY) stock saw a decline, ending the day at $810.43 which represents a decrease of $-0.65 or -0.08% from the prior close of $811.08. The stock opened at $804.27 and touched a low of $801.
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.
Eli Lilly & Co (LLY) Gets a Buy from Jefferies
Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of
How Eli Lilly is approaching GLP-1 marketing and what’s next
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, including with its GLP-1 medications.
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been making waves in the biopharmaceutical industry with its strong portfolio of drugs,
Wall Street Journal23d
Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal
Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...
Nasdaq3d
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...
The Financial Times26d
Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused ...
The Motley Fool21d
Has Eli Lilly Stock Peaked?
Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...
Why Does Jim Cramer Prefer Eli Lilly (LLY) Over Viking Therapeutics?
We recently published a list of Jim Cramer’s February Portfolio: Top 10 Stocks. In this article, we are going to take a look ...